ELEDON PHARMACEUTICALS, INC. — Net Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/11df194c-4c15-486f-b89c-004e0048003f/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-45.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-116164 |
| FY 2024 | $-36.2M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-042754 |
| FY 2023 | $-116.5M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-098575 |
| FY 2022 | $-88.0M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-011011 |
| FY 2021 | $-34.5M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-011698 |
| FY 2020 | $-22.8M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-016828 |
| FY 2019 | $-16.0M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-011260 |
| FY 2018 | $-14.1M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-009631 |
| FY 2017 | $-13.1M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-007314 |
| FY 2016 | $-5.7M | 2016-01-01 – 2016-12-31 | evidence 0001564590-18-007314 |
| FY 2015 | $-45.1M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-499163 |
| FY 2014 | $-23.3M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-107051 |
| FY 2013 | $-15.7M | 2013-01-01 – 2013-12-31 | evidence 0001193125-15-107051 |
| FY 2012 | $-9.6M | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-107051 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ELEDON PHARMACEUTICALS, INC. — all facts · Revenue · Operating Income